---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Epidemiology and eligible population inputs"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Epidemiology and eligible population inputs. Topics: ICER potential budget impact analysis: populations included, ICER potential budget impact analysis: eligible population and uptake, Source of the treated proportion used by ICER, Patient funnel for a hypothetical 1 million–member United States health plan, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics/epidemiology-and-eligible-population-inputs"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Epidemiology and eligible population inputs

<a id="heading-4.2.3"></a>

## 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

### ICER potential budget impact analysis: populations included

> “This includes the resistant hypertension population consisting of those on three or more antihypertensive medications and not meeting blood pressure goals (Population 1), and the population on two antihypertensive medications and not meeting blood pressure goals who did not tolerate a third medication (Population 2). We did not estimate the budget impact for the population of those on two antihypertensive medications and not meeting blood pressure goals who have not tried a third first-line medication (Population 3) because this specific population was not modeled in the cost-effectiveness model.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.3-2"></a>

### ICER potential budget impact analysis: eligible population and uptake

> “To estimate the size of Population 1 (those taking three or more antihypertensive medications but still not achieving blood pressure goals), we used inputs for the overall prevalence of hypertension among US adults (48.1%)”
> “the percentage of those with hypertension who are taking medication (51.2%)”
> “and the percentage of those taking medication who are being treated with three or more antihypertensive medications but still have uncontrolled hypertension (15%)”
> “Applying these sources to the overall adult population in the US averaged over the next five years (271,862,765) results in estimates of 10,042,828 eligible patients in the US. For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 2,008,565 patients per year.”
> “who are being treated with two antihypertensive medications and still have uncontrolled hypertension (17.9%)”
> “We then assumed that 21% of these have attempted a third antihypertensive medication and discontinued. This is a placeholder estimate based on available claims data reporting discontinuation rate of antihypertensive medications”
> “As a result, we estimated that 2,516,732 patients have uncontrolled hypertension and have attempted and discontinued a third antihypertensive medication (Population 2). For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 503,346 patients per year. Between Population 1 and Population 2 we estimated a total of 12,559,560 eligible patients.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.3-3"></a>

### Source of the treated proportion used by ICER

> “More than one-half of adults with hypertension were currently taking medication (51.2%) to lower blood pressure.”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-4.2.3-4"></a>

### Patient funnel for a hypothetical 1 million–member United States health plan

> “Based on US census and literature data, among a hypothetical 1 million–member US health plan, 194 140 individuals are adults diagnosed and treated for HTN.”
> “Based on Optum Market Clarity Data used in this study, 53.8% of treated patients have uHTN, corresponding to 104 494 patients in the standardized funnel.”
> “Among patients with uHTN, 64.7% receive 2+ AHTs (n = 67 584), of whom 45.1% receive 2 AHTs (n = 30 503) and 54.9% receive 3+ AHTs (n = 37 081).”
> “This patient funnel provides estimates of uHTN and rHTN prevalence among adult patients with HTN based on large-scale real-world data (i.e., 27.6% and 9.8%, respectively).”
> “The standardized HTN patient funnel can inform future economic analyses estimating the financial impact of interventions aimed at improving HTN management and patient care.”

Source: [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf)

<a id="topic-4.2.3-5"></a>

### Manufacturer target population and prescriber base

> “That is that third line or later. We think resistant is the natural opening space, and with experience, both from a physician standpoint and demand growing into the third-line usage.”
> “As you have heard us say before, when we look at where we have developed this molecule, third line or later, and in the United States who prescribes there, it is about 60,000 physicians that are responsible for half of the scripts third line or later.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
